Skip to main content
Top
Published in: BMC Neurology 1/2022

Open Access 01-12-2022 | Alzheimer's Disease | Research

Expression relationship and significance of NEAT1 and miR-27a-3p in serum and cerebrospinal fluid of patients with Alzheimer’s disease

Authors: Lijie He, Zongnan Chen, Jing Wang, Heqiang Feng

Published in: BMC Neurology | Issue 1/2022

Login to get access

Abstract

Objective

To explore the expression relationship and significance of long chain non-coding RNA nuclear-enriched abundant transcript 1 (LncRNA NEAT1) and miR-27a-3p in serum and cerebrospinal fluid of patients with Alzheimer’s disease (AD).

Methods

Sixty-six AD patients received by the Department of Neurology of our hospital from October 2019 to September 2021 were gathered, according to the Clinical Dementia Rating Scale (CDR) score, they were grouped into mild group (≤1 point, n = 41) and moderate-to-severe group (> 1 point, n = 25). Another 32 cases of serum and cerebrospinal fluid samples from outpatient physical examination personnel were regarded as the control group. The general materials on all subjects was recorded and cognition was assessed;real-time quantitative PCR was performed to measure the expression levels of miR-27a-3p and NEAT1 in serum and cerebrospinal fluid;enzyme-linked immunosorbent assay was performed to measure the protein levels of β-amyloid precursor protein cleaving enzyme 1 (BACE1), β-amyloid (Aβ) 40 and Aβ42 in cerebrospinal fluid;Spearman’s method was performed to analyze the correlation of serum miR-27a-3p and NEAT1 levels with MMSE and MoCA scores;Pearson method was performed to analyze the correlation between serum miR-27a-3p and NEAT1 levels and Aβ deposition standard uptake value ratio (SUVR) and cerebrospinal fluid miR-27a-3p, NEAT1, BACE1, Aβ42 and Aβ40 levels.

Results

The MMSE score, MoCA score, serum miR-27a-3p level, cerebrospinal fluid miR-27a-3p, Aβ42 levels and Aβ42/Aβ40 ratio of AD patients in mild group and moderate-to-severe group were all lower than those in the control group, and the moderate-to-severe group were lower than the mild group (all P < 0.05);the serum NEAT1 level, SUVR, and cerebrospinal fluid NEAT1 and BACE1 levels were higher than those in the control group, and the moderate-to-severe group were higher than the mild group (all P < 0.05). Serum NEAT1 level in AD patients was positively correlated with SUVR, cerebrospinal fluid NEAT1 and BACE1 (r = 0.350, 0.606, 0.341, all P < 0.05);serum miR-27a-3p level was positively correlated with cerebrospinal fluid miR-27a-3p level (r = 0.695, P < 0.05), and negatively correlated with SUVR and cerebrospinal fluid BACE1 level (r = − 0.521, − 0.447, both P < 0.05).

Conclusions

The expression trends of NEAT1 and miR-27a-3p in the serum and cerebrospinal fluid of AD patients are consistent, the level of NEAT1 is increased, and the level of miR-27a-3p is decreased. The levels of the two are negatively correlated, which is related to the degree of Aβ deposition in the brain of AD patients and is involved in the progression of AD.
Literature
1.
go back to reference Villain N, Dubois B. Alzheimer's disease including focal presentations. Semin Neurol. 2019;39(2):213–26.CrossRef Villain N, Dubois B. Alzheimer's disease including focal presentations. Semin Neurol. 2019;39(2):213–26.CrossRef
2.
go back to reference Ossenkoppele R, Pijnenburg YA, Perry DC, et al. The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features. Brain. 2015;138(9):2732–49.CrossRef Ossenkoppele R, Pijnenburg YA, Perry DC, et al. The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features. Brain. 2015;138(9):2732–49.CrossRef
3.
go back to reference Scheltens P, Blennow K, Breteler MM, et al. Alzheimer’s disease. Lancet. 2016;388(10043):505–17.CrossRef Scheltens P, Blennow K, Breteler MM, et al. Alzheimer’s disease. Lancet. 2016;388(10043):505–17.CrossRef
4.
go back to reference Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021;20:68–80.CrossRef Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021;20:68–80.CrossRef
5.
go back to reference Xu D, Dong P, Xiong Y, et al. MicroRNA-361-mediated inhibition of HSP90 expression and EMT in cervical cancer is counteracted by oncogenic lncRNA NEAT1. Cells. 2020;9:632.CrossRef Xu D, Dong P, Xiong Y, et al. MicroRNA-361-mediated inhibition of HSP90 expression and EMT in cervical cancer is counteracted by oncogenic lncRNA NEAT1. Cells. 2020;9:632.CrossRef
6.
go back to reference Feng Y, Gao L, Cui G, et al. LncRNA NEAT1 facilitates pancreatic cancer growth and metastasis through stabilizing ELF3 mRNA. Am J Cancer Res. 2020;10:237–48.PubMedPubMedCentral Feng Y, Gao L, Cui G, et al. LncRNA NEAT1 facilitates pancreatic cancer growth and metastasis through stabilizing ELF3 mRNA. Am J Cancer Res. 2020;10:237–48.PubMedPubMedCentral
7.
go back to reference Kou JT, Ma J, Zhu JQ, et al. LncRNA NEAT1 regulates proliferation, apoptosis and invasion of liver cancer. Eur Rev Med Pharmacol Sci. 2020;24:4152–60.PubMed Kou JT, Ma J, Zhu JQ, et al. LncRNA NEAT1 regulates proliferation, apoptosis and invasion of liver cancer. Eur Rev Med Pharmacol Sci. 2020;24:4152–60.PubMed
8.
go back to reference Jiang X, Guo S, Zhang Y, et al. LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p. Cell Signal. 2020;65:109422.CrossRef Jiang X, Guo S, Zhang Y, et al. LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p. Cell Signal. 2020;65:109422.CrossRef
9.
go back to reference Taiana E, Favasuli V, Ronchetti D, et al. Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. Leukemia. 2020;34:234–44.CrossRef Taiana E, Favasuli V, Ronchetti D, et al. Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. Leukemia. 2020;34:234–44.CrossRef
10.
go back to reference Yasmeen S, Kaur S, Mirza AH, et al. miRNA-27a-3p and miRNA-222-3p as novel modulators of phosphodiesterase 3a (PDE3A) in cerebral microvascular endothelial cells. Mol Neurobiol. 2019;56:5304–14.CrossRef Yasmeen S, Kaur S, Mirza AH, et al. miRNA-27a-3p and miRNA-222-3p as novel modulators of phosphodiesterase 3a (PDE3A) in cerebral microvascular endothelial cells. Mol Neurobiol. 2019;56:5304–14.CrossRef
11.
go back to reference Friedrich M, Heimer N, Stoehr C, et al. CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma. Sci Rep. 2020;10:6499.CrossRef Friedrich M, Heimer N, Stoehr C, et al. CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma. Sci Rep. 2020;10:6499.CrossRef
12.
go back to reference Dong M, Wang X, Guan Y, et al. MiR-27a-3p downregulation contributes to the development of occlusive bronchiolitis. Cell Stress Chaperones. 2019;24:883–9.CrossRef Dong M, Wang X, Guan Y, et al. MiR-27a-3p downregulation contributes to the development of occlusive bronchiolitis. Cell Stress Chaperones. 2019;24:883–9.CrossRef
13.
go back to reference Luo Y, Yang J, Zhang C, et al. Up-regulation of miR-27a promotes monocyte-mediated inflammatory responses in Kawasaki disease by inhibiting function of B10 cells. J Leukoc Biol. 2020;107:133–44.CrossRef Luo Y, Yang J, Zhang C, et al. Up-regulation of miR-27a promotes monocyte-mediated inflammatory responses in Kawasaki disease by inhibiting function of B10 cells. J Leukoc Biol. 2020;107:133–44.CrossRef
14.
go back to reference Ke S, Yang Z, Yang F, et al. Long noncoding RNA NEAT1 aggravates Aβ-induced neuronal damage by targeting miR-107 in Alzheimer's disease. Yonsei Med J. 2019;60:640–50.CrossRef Ke S, Yang Z, Yang F, et al. Long noncoding RNA NEAT1 aggravates Aβ-induced neuronal damage by targeting miR-107 in Alzheimer's disease. Yonsei Med J. 2019;60:640–50.CrossRef
15.
go back to reference Zhao MY, Wang GQ, Wang NN, et al. The long-non-coding RNA NEAT1 is a novel target for Alzheimer's disease progression via miR-124/BACE1 axis. Neurol Res. 2019;41:489–97.CrossRef Zhao MY, Wang GQ, Wang NN, et al. The long-non-coding RNA NEAT1 is a novel target for Alzheimer's disease progression via miR-124/BACE1 axis. Neurol Res. 2019;41:489–97.CrossRef
16.
go back to reference Sala Frigerio C, Lau P, Salta E, et al. Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease. Neurology. 2013;81:2103–6.CrossRef Sala Frigerio C, Lau P, Salta E, et al. Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease. Neurology. 2013;81:2103–6.CrossRef
17.
go back to reference Dong LX, Zhang YY, Bao HL, et al. NEAT1 promotes Alzheimer's disease by down regulating micro-27a-3p. Am J Transl Res. 2021;13:8885–96.PubMedPubMedCentral Dong LX, Zhang YY, Bao HL, et al. NEAT1 promotes Alzheimer's disease by down regulating micro-27a-3p. Am J Transl Res. 2021;13:8885–96.PubMedPubMedCentral
18.
go back to reference Jianping J, Cuibai W. 2018 Chinese guidelines for the diagnosis and treatment of dementia and cognitive impairment (II): guidelines for the diagnosis and treatment of Alzheimer’s disease. Natl Med J China. 2018;98:971–7. Jianping J, Cuibai W. 2018 Chinese guidelines for the diagnosis and treatment of dementia and cognitive impairment (II): guidelines for the diagnosis and treatment of Alzheimer’s disease. Natl Med J China. 2018;98:971–7.
19.
go back to reference Jianping J, Yi T. 2018 Chinese guidelines for diagnosis and treatment of dementia and cognitive impairment (6): pre dementia stage of Alzheimer's disease. Natl Med J China. 2018;98:1457–60. Jianping J, Yi T. 2018 Chinese guidelines for diagnosis and treatment of dementia and cognitive impairment (6): pre dementia stage of Alzheimer's disease. Natl Med J China. 2018;98:1457–60.
20.
go back to reference Smith PY, Hernandez-Rapp J, Jolivette F, et al. miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo. Hum Mol Genet. 2015;24:6721–35.CrossRef Smith PY, Hernandez-Rapp J, Jolivette F, et al. miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo. Hum Mol Genet. 2015;24:6721–35.CrossRef
21.
go back to reference Li QS, Cai D. Integrated miRNA-Seq and mRNA-Seq study to identify miRNAs associated with Alzheimer's disease using post-mortem brain tissue samples. Front Neurosci. 2021;15:620–899. Li QS, Cai D. Integrated miRNA-Seq and mRNA-Seq study to identify miRNAs associated with Alzheimer's disease using post-mortem brain tissue samples. Front Neurosci. 2021;15:620–899.
22.
go back to reference El Fatimy R, Li S, Chen Z, et al. miRRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways. Acta Neuropathol. 2018;136:537–55.CrossRef El Fatimy R, Li S, Chen Z, et al. miRRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways. Acta Neuropathol. 2018;136:537–55.CrossRef
23.
go back to reference Zeng T, Ni H, Yu Y, et al. BACE1-AS prevents BACE1 mRNA degradation through the sequestration of BACE1-targeting miRNAs. J Chem Neuroanat. 2019;98:87–96.CrossRef Zeng T, Ni H, Yu Y, et al. BACE1-AS prevents BACE1 mRNA degradation through the sequestration of BACE1-targeting miRNAs. J Chem Neuroanat. 2019;98:87–96.CrossRef
24.
go back to reference Yue D, Guanqun G, Jingxin L, et al. Silencing of long noncoding RNA XIST attenuated Alzheimer's disease-related BACE1 alteration through miR-124. Cell Biol Int. 2020;44:630–6.CrossRef Yue D, Guanqun G, Jingxin L, et al. Silencing of long noncoding RNA XIST attenuated Alzheimer's disease-related BACE1 alteration through miR-124. Cell Biol Int. 2020;44:630–6.CrossRef
25.
go back to reference Hampel H, Vassar R, De Strooper B, et al. The β-Secretase BACE1 in Alzheimer's disease. Biol Psychiatry. 2021;89:745–56.CrossRef Hampel H, Vassar R, De Strooper B, et al. The β-Secretase BACE1 in Alzheimer's disease. Biol Psychiatry. 2021;89:745–56.CrossRef
26.
go back to reference Yan R, Vassar R. Targeting the β secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014;13:319–29.CrossRef Yan R, Vassar R. Targeting the β secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014;13:319–29.CrossRef
27.
go back to reference Zott B, Simon MM, Hong W, et al. A vicious cycle of β amyloid-dependent neuronal hyperactivation. Science. 2019;365:559–65.CrossRef Zott B, Simon MM, Hong W, et al. A vicious cycle of β amyloid-dependent neuronal hyperactivation. Science. 2019;365:559–65.CrossRef
28.
go back to reference Nguyen LD, Chau RK, Krichevsky AM. Small molecule drugs targeting non-coding RNAs as treatments for Alzheimer's disease and related dementias. Genes (Basel). 2021;12:2005.CrossRef Nguyen LD, Chau RK, Krichevsky AM. Small molecule drugs targeting non-coding RNAs as treatments for Alzheimer's disease and related dementias. Genes (Basel). 2021;12:2005.CrossRef
Metadata
Title
Expression relationship and significance of NEAT1 and miR-27a-3p in serum and cerebrospinal fluid of patients with Alzheimer’s disease
Authors
Lijie He
Zongnan Chen
Jing Wang
Heqiang Feng
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2022
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-022-02728-9

Other articles of this Issue 1/2022

BMC Neurology 1/2022 Go to the issue